| Cross-sectional case-control studies  

VARICELLA ZOSTER VIRUS-INDUCED NEUROLOGICAL DISEASE AFTER COVID-19 VACCINATION: A RETROSPECTIVE MONOCENTRIC STUDY

In this study, the authors retrospectively evaluated patients admitted to their clinic and diagnosed with VZV-ND during the COVID-19 vaccination campaign (January–April 2021) and in the same months in the previous two years.

The description of every possible adverse effect or event related to vaccines is mandatory during the ongoing worldwide COVID-19 vaccination program. Although cases of cutaneous varicella zoster virus (VZV) reactivation after COVID-19 vaccination have been increasingly reported in literature and database sets, a description of VZV-induced neurological disease (VZV-ND) is still lacking. In this study, the authors retrospectively evaluated patients admitted to their clinic and diagnosed with VZV-ND during the COVID-19 vaccination campaign (January–April 2021) and in the same months in the previous two years. They identified three patients with VZV-ND after COVID-19 vaccination and 19 unvaccinated VZV-ND cases as controls. In the case–control analysis, the two groups showed no difference in clinical features, results of diagnostic investigations, and outcome. Thus, VZV reactivation with neurological involvement might be a possible event triggered by COVID-19 vaccination, but the benefit following COVID-19 vaccination overcomes significantly the potential risk associated with a VZV reactivation.

Abu-Rumeileh, S., Mayer, B., Still, V. et al. Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study. J Neurol (2021). https://doi.org/10.1007/s00415-021-10849-3.